First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer
Abstract
Background We assessed the safety, tolerability, and pharmacokinetics of mitochondrial complex 1 inhibitor ASP4132. Methods This phase I dose-escalation/dose-expansion study enrolled patients with treatment refractory advanced solid tumors to assess safety, dose-limiting toxicities (DLTs), efficacy and pharmacokinetic or oral ASP4132. Results Overall, 39 patients received ASP4132. Acceptable tolerability of ASP4132 5 mg in the first patient led...
Paper Details
Title
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer
Published Date
Apr 8, 2021
Journal
Volume
39
Issue
5
Pages
1348 - 1356
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History